LDOS is trading at $125.96, still digesting one of the sharpest single-quarter de-ratings in recent memory — and this week the options market sent its clearest distress signal yet.
Put demand has surged to near-extreme levels. The put/call ratio hit 1.21 on Tuesday and reached 1.34 on Monday — both readings well above the 20-day average of 0.73. The z-score of 2.57 places this week's hedging activity more than two and a half standard deviations above the recent norm, the second-highest defensive positioning in the past year behind only the 52-week PCR peak of 1.40. That's not routine portfolio insurance; that's active protection being bought at elevated prices by investors who have already watched the stock fall 19% over the past month. The shift is stark: for most of April and into early May, the PCR sat in the 0.64–0.69 band. It broke sharply higher mid-week of last week and hasn't retreated.
Short positioning, by contrast, tells a much quieter story. SI as a percentage of free float is running at just 2.7%, and the absolute share count has actually declined from its mid-April peak of roughly 3.75 million shares to 3.40 million today. The lending market is about as loose as it gets — availability is running at nearly 4,900%, meaning the pool of shares available to borrow dwarfs actual short interest by nearly 49 times. Borrowing costs remain negligible at 0.39% annualised, up ~15% on the week but still at the lower end of where they've traded all year. There is no short-squeeze pressure here, and no sign of an aggressive short build. The ORTEX short score of 33.6 reflects this — it has drifted lower since early May, not higher.
The Street is still trying to find the floor. Every analyst who has updated since the May 5 print moved their target lower. Citi maintained its Buy but took its target from $232 to $178. RBC held Outperform but cut to $180 from $215. Stifel's Hold came with a trim to $193. BofA and Truist, which lowered ahead of earnings, are both still Buy-rated with targets of $200 and $195 respectively. The consensus mean target is now $190 — implying roughly 51% upside from current levels. The width of that gap is notable, but it reflects how quickly the targets were revised downward rather than bullish conviction. The bear case centres on the Medical Exam contract, which reportedly accounts for a meaningful portion of EBITDA and faces headwinds, alongside the margin compression visible in Q1. The bull case rests on Entrust acquisition synergies and the company's positioning in defence IT and classified programmes.
On valuation, the PE multiple has compressed to just under 10x — down roughly 2.3 turns over the past month — while EV/EBITDA is running at 7.9x. Both readings are at the lower end of where LDOS has historically traded. The EV/EBIT factor score ranks in the 86th percentile of the universe, suggesting the stock screens as cheap relative to earnings power. But cheap multiples alone haven't been enough to stabilise the name; the momentum score remains a clear drag, with relative strength negative across all windows and the stock at roughly 66% of its 52-week high.
Insider activity has been one-directional throughout the decline. The CEO sold 2,530 shares at $148.81 on May 5 — earnings day — and an additional 3,245 shares in early March at $177.89. A Group President and an independent director also sold in early May. Net insider activity over the past 90 days totals roughly $3.5 million in sales. These were relatively small transactions as a percentage of the company, but the pattern of consistent selling into weakness — rather than any buying — is worth noting as the stock approaches multi-year lows.
Among correlated peers, the picture is mixed. BAH gained 2.1% on the week — diverging meaningfully from LDOS's 1.9% decline — while AMTM dropped 6.9%, the worst performer in the group. SAIC edged up 1.4%, and CACI was roughly flat. The spread in peer performance suggests sector-wide budget concerns aren't the primary driver of LDOS's weakness; this remains a stock-specific story centred on the May earnings miss and contract execution risk.
The next catalyst is the Q2 earnings date on August 4. Between now and then, the question the market is sitting with is whether the Medical Exam contract headwinds worsen and whether the Entrust acquisition begins to offset margin pressure at the operating line — or whether the compression visible in Q1 deepens before any recovery takes hold.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
